Evaluation of Rivaroxaban as Anticoagulant for Treatment of Left Ventricle (LV) Apical Clot

ivaroxaban is a direct Inhibitor of Activated Factor X. this Drug is as Oral Monotherapy for Prophylaxis and Treatment of Acute DVT and Pulmonary Emboli. In this Study we evaluated this Drug for Treatment of LV Apical Clot after Acute Myocardial Infarction (AMI).Methods: 20 Patients with LV Apical Clot after Myocardial Infarction were studied. Rivaroxaban (20 mg / daily) was given for 3 Months for all of Patients. Echocardiography with Vivid S60 was done after 3 Months of Treatment and Results of this Study were Analyzed by SPSS 23.Results: 20 Patients have LV Apical Clot after AMI. 16 Patients were Male, 4 Female. Mean age 56±11 Years old. Evaluation of Patients with Echo after 3 Months Showed no Clot in LV Apex.Conclusion: This Study Showed Medical Therapy with Rivaroxaban (20 mg / daily) for LV Apical Clot after AMI for 3 Months is Effective, but this needs More Study.

Keywords:

Anticoagulant Therapy , Rivaroxaban , Left Ventricle Apical Clot , Acute Myocardial Infarction